Annual EBITDA
-$364.78 M
-$130.96 M-56.01%
December 31, 2023
Summary
- As of February 7, 2025, TVTX annual EBITDA is -$364.78 million, with the most recent change of -$130.96 million (-56.01%) on December 31, 2023.
- During the last 3 years, TVTX annual EBITDA has fallen by -$219.62 million (-151.29%).
- TVTX annual EBITDA is now -388.12% below its all-time high of $126.61 million, reached on December 31, 2015.
Performance
TVTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$40.82 M
+$15.61 M+27.67%
September 30, 2024
Summary
- As of February 7, 2025, TVTX quarterly EBITDA is -$40.82 million, with the most recent change of +$15.61 million (+27.67%) on September 30, 2024.
- Over the past year, TVTX quarterly EBITDA has increased by +$35.40 million (+46.44%).
- TVTX quarterly EBITDA is now -127.41% below its all-time high of $148.91 million, reached on September 30, 2015.
Performance
TVTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$296.56 M
+$34.11 M+10.32%
September 30, 2024
Summary
- As of February 7, 2025, TVTX TTM EBITDA is -$296.56 million, with the most recent change of +$34.11 million (+10.32%) on September 30, 2024.
- Over the past year, TVTX TTM EBITDA has increased by +$29.68 million (+9.10%).
- TVTX TTM EBITDA is now -316.62% below its all-time high of $136.91 million, reached on September 30, 2015.
Performance
TVTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TVTX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -56.0% | +46.4% | +9.1% |
| 3 y3 years | -151.3% | +46.6% | -6.0% |
| 5 y5 years | -397.0% | +46.6% | -6.0% |
TVTX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -174.4% | at low | at high | +66.8% | -67.9% | +18.1% |
| 5 y | 5-year | -240.2% | at low | -435.3% | +66.8% | -441.1% | +18.1% |
| alltime | all time | -388.1% | at low | -127.4% | +66.8% | -316.6% | +18.1% |
Travere Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$40.82 M(-27.7%) | -$296.56 M(-10.3%) |
| Jun 2024 | - | -$56.43 M(-54.2%) | -$330.67 M(-8.7%) |
| Mar 2024 | - | -$123.09 M(+61.5%) | -$362.32 M(+11.1%) |
| Dec 2023 | -$364.78 M(+56.0%) | -$76.22 M(+1.7%) | -$326.25 M(-0.1%) |
| Sep 2023 | - | -$74.93 M(-14.9%) | -$326.43 M(-1.9%) |
| Jun 2023 | - | -$88.08 M(+1.2%) | -$332.58 M(+10.7%) |
| Mar 2023 | - | -$87.02 M(+13.9%) | -$300.41 M(+7.4%) |
| Dec 2022 | -$233.81 M(+75.9%) | -$76.40 M(-5.8%) | -$279.70 M(-2.7%) |
| Sep 2022 | - | -$81.09 M(+45.1%) | -$287.46 M(+25.4%) |
| Jun 2022 | - | -$55.90 M(-15.7%) | -$229.19 M(+14.1%) |
| Mar 2022 | - | -$66.31 M(-21.2%) | -$200.79 M(+13.7%) |
| Dec 2021 | -$132.92 M(-8.4%) | -$84.16 M(+268.7%) | -$176.63 M(-13.1%) |
| Sep 2021 | - | -$22.82 M(-17.0%) | -$203.17 M(+6.0%) |
| Jun 2021 | - | -$27.49 M(-34.8%) | -$191.67 M(+6.7%) |
| Mar 2021 | - | -$42.16 M(-61.9%) | -$179.69 M(+23.8%) |
| Dec 2020 | -$145.16 M(+35.4%) | -$110.70 M(+877.9%) | -$145.16 M(+164.9%) |
| Sep 2020 | - | -$11.32 M(-27.1%) | -$54.80 M(-22.3%) |
| Jun 2020 | - | -$15.52 M(+103.5%) | -$70.57 M(-16.0%) |
| Mar 2020 | - | -$7.63 M(-62.5%) | -$84.03 M(-21.6%) |
| Dec 2019 | -$107.21 M(+46.1%) | -$20.34 M(-24.9%) | -$107.21 M(+26.9%) |
| Sep 2019 | - | -$27.09 M(-6.5%) | -$84.49 M(-18.9%) |
| Jun 2019 | - | -$28.97 M(-6.0%) | -$104.17 M(+13.7%) |
| Mar 2019 | - | -$30.81 M(-1391.3%) | -$91.66 M(+24.7%) |
| Dec 2018 | -$73.39 M(+103.1%) | $2.39 M(-105.1%) | -$73.49 M(-9.6%) |
| Sep 2018 | - | -$46.77 M(+184.1%) | -$81.34 M(+68.4%) |
| Jun 2018 | - | -$16.46 M(+30.2%) | -$48.31 M(+15.3%) |
| Mar 2018 | - | -$12.65 M(+131.5%) | -$41.91 M(+10.3%) |
| Dec 2017 | -$36.14 M | -$5.46 M(-60.2%) | -$38.00 M(+4.1%) |
| Sep 2017 | - | -$13.74 M(+36.6%) | -$36.52 M(-25.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2017 | - | -$10.06 M(+15.1%) | -$49.03 M(-11.9%) |
| Mar 2017 | - | -$8.74 M(+119.5%) | -$55.65 M(+51.6%) |
| Dec 2016 | -$36.71 M(-129.0%) | -$3.98 M(-84.8%) | -$36.71 M(-11.4%) |
| Sep 2016 | - | -$26.25 M(+57.4%) | -$41.42 M(-131.0%) |
| Jun 2016 | - | -$16.68 M(-263.5%) | $133.75 M(+1.6%) |
| Mar 2016 | - | $10.20 M(-217.4%) | $131.60 M(+3.9%) |
| Dec 2015 | $126.61 M(-270.2%) | -$8.69 M(-105.8%) | $126.61 M(-7.5%) |
| Sep 2015 | - | $148.91 M(-890.7%) | $136.91 M(-636.7%) |
| Jun 2015 | - | -$18.83 M(-461.4%) | -$25.51 M(-501.9%) |
| Mar 2015 | - | $5.21 M(+223.1%) | $6.35 M(-130.5%) |
| Dec 2014 | -$74.41 M(+203.0%) | $1.61 M(-111.9%) | -$20.80 M(-21.5%) |
| Sep 2014 | - | -$13.50 M(-203.7%) | -$26.48 M(+46.5%) |
| Jun 2014 | - | $13.02 M(-159.4%) | -$18.08 M(-50.0%) |
| Mar 2014 | - | -$21.93 M(+439.1%) | -$36.15 M(+125.2%) |
| Dec 2013 | -$24.56 M(-18.5%) | -$4.07 M(-20.2%) | -$16.05 M(+33.9%) |
| Sep 2013 | - | -$5.10 M(+1.1%) | -$11.98 M(+74.0%) |
| Jun 2013 | - | -$5.05 M(+175.3%) | -$6.89 M(+273.7%) |
| Mar 2013 | - | -$1.83 M(>+9900.0%) | -$1.84 M(>+9900.0%) |
| Dec 2012 | -$30.13 M(>+9900.0%) | - | - |
| Nov 2012 | - | -$3200.00(+6.7%) | -$13.00 K(+1.6%) |
| Aug 2012 | - | -$3000.00(0.0%) | -$12.80 K(0.0%) |
| May 2012 | - | -$3000.00(-21.1%) | -$12.80 K(0.0%) |
| Feb 2012 | - | -$3800.00(+26.7%) | -$12.80 K(+1.6%) |
| Feb 2012 | -$12.80 K(+0.8%) | - | - |
| Nov 2011 | - | -$3000.00(0.0%) | -$12.60 K(-0.8%) |
| Aug 2011 | - | -$3000.00(0.0%) | -$12.70 K(+30.9%) |
| May 2011 | - | -$3000.00(-16.7%) | -$9700.00(+44.8%) |
| Feb 2011 | -$12.70 K | -$3600.00(+16.1%) | -$6700.00(+116.1%) |
| Nov 2010 | - | -$3100.00 | -$3100.00 |
FAQ
- What is Travere Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Travere Therapeutics?
- What is Travere Therapeutics annual EBITDA year-on-year change?
- What is Travere Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Travere Therapeutics?
- What is Travere Therapeutics quarterly EBITDA year-on-year change?
- What is Travere Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Travere Therapeutics?
- What is Travere Therapeutics TTM EBITDA year-on-year change?
What is Travere Therapeutics annual EBITDA?
The current annual EBITDA of TVTX is -$364.78 M
What is the all time high annual EBITDA for Travere Therapeutics?
Travere Therapeutics all-time high annual EBITDA is $126.61 M
What is Travere Therapeutics annual EBITDA year-on-year change?
Over the past year, TVTX annual EBITDA has changed by -$130.96 M (-56.01%)
What is Travere Therapeutics quarterly EBITDA?
The current quarterly EBITDA of TVTX is -$40.82 M
What is the all time high quarterly EBITDA for Travere Therapeutics?
Travere Therapeutics all-time high quarterly EBITDA is $148.91 M
What is Travere Therapeutics quarterly EBITDA year-on-year change?
Over the past year, TVTX quarterly EBITDA has changed by +$35.40 M (+46.44%)
What is Travere Therapeutics TTM EBITDA?
The current TTM EBITDA of TVTX is -$296.56 M
What is the all time high TTM EBITDA for Travere Therapeutics?
Travere Therapeutics all-time high TTM EBITDA is $136.91 M
What is Travere Therapeutics TTM EBITDA year-on-year change?
Over the past year, TVTX TTM EBITDA has changed by +$29.68 M (+9.10%)